Education
About Us
Working with TipRanks
Follow Us
Purple Biotech (PPBT)
NASDAQ:PPBT
Total Valuation
Purple Biotech has a market cap or net worth of $6.72M. The enterprise value is ―.
Market Cap$6.72M
Enterprise Value―
Share Statistics
Purple Biotech has 2,779,482 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,779,482
Owned by Insiders―
Owned by Institutions0.61%
Financial Efficiency
Purple Biotech’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -33.11%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-33.11%
Return on Capital Employed (ROCE)-0.33
Revenue Per Employee0.00
Profits Per Employee-808.78K
Employee Count9
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Purple Biotech is -0.11. Purple Biotech’s PEG ratio is >-0.01.
PE Ratio-0.11
PS Ratio0.00
PB Ratio0.01
Price to Fair Value0.02
Price to FCF>-0.01
Price to Operating Cash Flow-0.03
PEG Ratio>-0.01
Income Statement
In the last 12 months, Purple Biotech had revenue of 0.00 and earned -7.24M in profits. Earnings per share was -0.21.
Revenue0.00
Gross Profit0.00
Operating Income-11.01M
Pretax Income-7.28M
Net Income-7.24M
EBITDA-7.05M
Earnings Per Share (EPS)-0.21
Cash Flow
In the last 12 months, operating cash flow was -14.37M and capital expenditures 0.00, giving a free cash flow of -14.37M billion.
Operating Cash Flow-14.37M
Free Cash Flow-14.37M
Free Cash Flow per Share-5.17
Dividends & Yields
Purple Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.25
52-Week Price Change207.69%
50-Day Moving Average2.53
200-Day Moving Average3.03
Relative Strength Index (RSI)49.12
Average Volume (3m)201.43K
Important Dates
Purple Biotech upcoming earnings date is Aug 14, 2025, TBA Not Confirmed.
Last Earnings DateMay 21, 2025
Next Earnings DateAug 14, 2025
Ex-Dividend Date―
Financial Position
Purple Biotech as a current ratio of 2.23, with Debt / Equity ratio of 0.56%
Current Ratio2.23
Quick Ratio2.23
Debt to Market Cap0.00
Net Debt to EBITDA1.02
Interest Coverage Ratio-268.41
Taxes
In the past 12 months, Purple Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Purple Biotech EV to EBITDA ratio is -22.02, with an EV/FCF ratio of -10.81.
EV to Sales0.00
EV to EBITDA-22.02
EV to Free Cash Flow-10.81
EV to Operating Cash Flow-10.81
Balance Sheet
Purple Biotech has $8.52M in cash and marketable securities with $183.00K in debt, giving a net cash position of -$8.34M billion.
Cash & Marketable Securities$8.52M
Total Debt$183.00K
Net Cash-$8.34M
Net Cash Per Share-$3.00
Tangible Book Value Per Share$0.15
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Purple Biotech is $33.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$33.00
Price Target Upside1275.00% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast71.57%